|
|
1 vaccine dose (b)
(n =10)
|
2 vaccine doses (c)
(n =72)
|
|
Age, mean (SD), yr** |
90.3 (7.4) |
83.8 (8.4) |
89.1 (7.8) |
0.06 |
Sex, n (%)****
Female
Male
|
15 (71.4)
6 (28.6%)
|
8 (80.0)
2 (20.0)
|
56 (77.8)
16 (22.2)
|
0.87
|
Charlson index (median, IQR) [range] **
|
6 (6.0-8.0)
[4-15]
|
7.0 (5.0-8.0)
5-9
|
7.0 (6.0-8.0)
3-15
|
0.96
|
Prior SARS-CoV-2-positive RT-PCR, n (%)*** |
1 (4.8) |
0 (0) |
3 (4.2) |
1.00 |
First positive RT-PCR cycle threshold, median (IQR) **** |
26.0
(23.0-32.0) |
24.85 (20.4 ; 28.0) |
24.00 (19.2 ; 28.6) |
0.74 |
Cycle threshold of the second RT-PCR*, median (IQR) **** |
30.3
(27-35.2) |
30.7 (23.1 ; 34.5) |
27.00 (21.0 ; 31.7) |
0.21 |
Symptoms, n (%)***
Asymptomatic
Mild
Severe
|
2 (9.5)
4 (19.1)
10 (47.6)
|
6 (60.0)
2 (20.0)
0
|
31 (43.7)
23 (31.0)
15 (21.1)
|
0.002
0.01 (a vs b),
0.002 (a vs c)
0.09 (b vs c)
|
Deaths, n (%)*** |
5 (23.8) |
2 (20.0) |
3 (4.2) |
0.002 (a vs
c) |
SARS-CoV-2 IgG levels
- N-protein IgG > 0.8 signal to cutoff ratio, n (%)**
- SARS-RBD-IgG (AU/mL) *****
<50
51-1,050
1,051-4,160
>4,160
|
n =10
2 (20.0)
6 (60.0)
3 (30.0)
0 (0)
1 (10)
|
n =7
1 (14.3)
1 (14.3)
5 (71.4)
1 (14.3)
0 (0)
|
n =49
4 (8)
5 (10.2)
22 (44.9)
15 (30.6)
7 (14.3)
|
0.29
0.010.01 (a vs c)
|
Nucleocapide antigenaemia titer **, median (IQR)[range] ******
|
n = 7
43.0 (2.9-150.2)
[0.7-555.2)
|
n =5
1.8 (0.5-3.0)
[0.2-12.5]
|
n =37
1.5 (-0.4-16-6)
[-1.5-328-4]
|
0.03
0.004 (a vs c)
|